Prospective Value Of Serologic Antibodies In Chinese Patients With Inflammation Bowel Disease

Yulan Ye,Liping Zhang,Tong Hu,Weichang Chen,Zhi Pang
2019-01-01
Abstract:Serological antibodies have been widely applied for diagnostics and potential clinical phenotypes of inflammatory bowel disease (IBD). The aim of this prospective study was to assess the clinical value of multiple antibodies, including anti-neutrophil cytoplasmic antibody (ANCA), anti-Saccharomyces cerevisiae antibody (ASCA), Escherichia coli outer membrane porin C antibody (anti-OmpC), anti glycoprotein 2 antibody (GP2), and goblet cell antibody (GAB), by means of ELISA testing, in Chinese patients with inflammation bowel disease. The study investigated 130 Crohn's disease (CD) and 120 ulcerative colitis (UC) patients, compared with 80 healthy subjects. IBD phenotype was classified according to the Montreal classification. A combination of ASCA IgA and IgG had a sensitivity of 58.5% in CD. ANCA showed a sensitivity of 46.7% for UC. Prevalence of anti-OmpC (IgA) and GP2 (IgG) were significantly higher in CD patients than UC patients. Positivity of GAB (IgG) was higher in UC than in CD. Hence, a combination of ASCA/anti-OmpC IgA/GP2 (IgG) showed the best specificity in distinguishing CD from UC. In CD, ASCA IgG, anti-OmpC IgA and GP2 (IgG) were identified to be greater in complicated CD patients (B2/B3) than in simple phenotype (B1) patients. Furthermore, positivity of ANCA was associated with disease activity of UC. GAB (IgG) positivity implied extensive location in UC. Even with a relatively low prevalence, this study suggests certain serological antibodies as biomarkers for disease phenotypes and behavior in IBD.
What problem does this paper attempt to address?